Please assess the completion status of the following clinical trial:

Trial Title: Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Undergoing distal or midshaft osteotomy for bunion correction, 1st MTP Fusion, or cheilectomy~Exclusion Criteria:~* Age less than 18~* Unable to read/write English~* Dementia, history of dementia, or other significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting~* Weight \<70 kg~* Allergy to local anesthetics~* History of long-acting opioid use or opioid tolerance (any patient receiving at least 30 mg of oxycodone or equivalent per day (e.g., 6 tabs of Percocet 5/325 mg) regularly for approximately 7 days or more OR who require increased analgesic doses for a period long enough to develop tolerance to the effects of the opioid including analgesia and sedation)~* Any history of opioid misuse, illicit or prescription~* Prior MTP joint correction on the surgical limb~* Midfoot and hindfoot procedures performed concurrently, on the same day~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regional Block (Type: ACTIVE_COMPARATOR): Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
- Regional Block Plus Exparel (Type: EXPERIMENTAL): Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.

Based on this trial design, predict the completion outcome and termination type (if applicable).